Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review.

To review clinical evidence for current and emerging treatments for patients with acute myeloid leukemia (AML) who are ineligible for first-line induction chemotherapy. A systematic literature review was performed (28 October 2021) to identify clinical outcomes including overall survival (OS), event-free survival (EFS), relapse-free survival (RFS) and adverse events (AEs). Of 233 references that met prespecified criteria, 26 studies were included.